Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

Standard of care for neo-adjuvant therapy in HER 2 and triple negative subtype

Dr Fatima Cardoso – Champalimaud Cancer Center, Lisbon, Portugal
Standard of care for neo-adjuvant therapy in HER 2  and triple negative subtype ( Dr Fatima Cardoso – Champalimaud Cancer Center, Lisbon, Portugal )
9 Oct 2012

Putting the theory of personalised medicine into practice

Prof Fabrice Andre, Dr Ramesh Ramanathan, Prof Peter Harper and Prof Robert Leonard
Putting the theory of personalised medicine into practice ( Prof Fabrice Andre, Dr Ramesh Ramanathan, Prof Peter Harper and Prof Robert Leonard )
8 Oct 2012

Personalised cancer medicine and research: Today’s best practice

Prof José Baselga - Massachusetts General Hospital, Boston, USA
Personalised cancer medicine and research: Today’s best practice ( Prof José Baselga - Massachusetts General Hospital, Boston, USA )
5 Oct 2012

Too few women being offered breast-conserving treatment?

Dr Carmen Criscitiello - European Institute of Oncology in Milan, Italy
Too few women being offered breast-conserving treatment? ( Dr Carmen Criscitiello - European Institute of Oncology in Milan, Italy )
30 Sep 2012

Molecular stratification of breast cancer: reaching the clinic

Prof Carlos Caldas - University of Cambridge, UK
Molecular stratification of breast cancer: reaching the clinic ( Prof Carlos Caldas - University of Cambridge, UK )
25 Jul 2012

Phase 1-2 results for oral proteasome inhibitor MLN9708 for multiple myeloma (Spanish)

Dr Rafael Fonseca – Mayo Clinic, Arizona, USA
Phase 1-2 results for oral proteasome inhibitor MLN9708 for multiple myeloma (Spanish) ( Dr Rafael Fonseca – Mayo Clinic, Arizona, USA )
20 Jun 2012

Effects of lapatinib and trastuzumab on progression free survival

Dr Nancy Lin – Dana Farber Cancer Institute, Boston, MA, USA
Effects of lapatinib and trastuzumab on progression free survival ( Dr Nancy Lin – Dana Farber Cancer Institute, Boston, MA, USA )
15 Jun 2012

Intermittent hormonal therapy versus continuous therapy for advanced prostate cancer

Dr Maha Hussain - University of Michigan, Ann Arbor, USA
Intermittent hormonal therapy versus continuous therapy for advanced prostate cancer ( Dr Maha Hussain - University of Michigan, Ann Arbor, USA )
3 Jun 2012

Intermittent hormonal therapy less effective than continuous therapy when treating advanced prostate cancer

Dr Maha Hussain - University of Michigan, Ann Arbor, USA
Intermittent hormonal therapy less effective than continuous therapy when treating advanced prostate cancer ( Dr Maha Hussain - University of Michigan, Ann Arbor, USA )
3 Jun 2012

Highlights and goals of IMPAKT 2012

Prof Martine Piccart – Jules Bordet Institute, Brussels, Belgium
Highlights and goals of IMPAKT 2012 ( Prof Martine Piccart – Jules Bordet Institute, Brussels, Belgium )
17 May 2012

Endocrine therapy and endocrine resistant breast cancer

Prof Mitch Dowsett – The Institute for Cancer Research, London, UK
Endocrine therapy and endocrine resistant breast cancer ( Prof Mitch Dowsett – The Institute for Cancer Research, London, UK  )
17 May 2012

Targeting DNA damage response and repair excluding PARP for triple negative breast cancer

Prof Thomas Helleday - Karolinska Institutet, Stockholm, Sweden
Targeting DNA damage response and repair excluding PARP for triple negative breast cancer ( Prof Thomas Helleday - Karolinska Institutet, Stockholm, Sweden )
17 May 2012